2 results
Approved WMOCompleted
To investigate the bleeding pattern and cycle control parameters of the transdermal contraceptive patch (material no. 80876395, FC Patch Low containing 0.55 mg EE and 2.1 mg GSD) in comparison to the EVRA patch (containing 0.6 mg EE and 6 mg NGMN).
Approved WMORecruiting
- The objective of the proposed clinical trial is to evaluate the safety and effectiveness of the Navitor Transcatheter Aortic Heart Valve in patients with severe, symptomatic aortic stenosis who are at intermediate or low risk of surgical mortality…